扶正化瘀胶囊治疗日本血吸虫病肝纤维化的效果  

Effect of Fuzheng Huayu capsule treating liver fibrosis due to Asiatic schistosomiasis

作　　者：黎晓琴 

机构地区：[1]江西省进贤县三里血防站,江西进贤331709

出　　处：《中国当代医药》2015年第20期136-138,共3页China Modern Medicine

摘　　要：目的 评价扶正化瘀胶囊治疗日本血吸虫病肝纤维化的效果,探讨其临床适用性。方法 选择2012年5月-2013年5月于本站就诊的80例日本血吸虫病肝纤维化患者,将其简单随机分为试验组40例和对照组40例。对照组患者给予常规基础治疗,试验组在对照组基础上联合扶正化瘀胶囊治疗,观察两组患者治疗前后的肝功能指标（包括ALT、AST、TBi L、Alb和Glb）、肝纤维化指标（包括HA、PC-Ⅲ、Ⅳ-C和LN）、肝组织中转化生长因子（TGF-β1）及用药后的不良反应情况。结果 治疗前,两组患者的肝功能指标、肝纤维化指标和TGF-β1水平比较,差异均无统计学意义（P〉0.05）;治疗后,肝功能指标、肝纤维化指标和TGF-β1均明显改善,且试验组患者的改善情况均优于对照组（P〈0.05）。结论 扶正化瘀胶囊治疗日本血吸虫病肝纤维化的效果显著,可明显改善肝功能,安全可靠,适合临床长期推广应用。Objective To evaluate the effect of Fuzheng Huayu capsule treating liver fibrosis due to Asiatic schistosomiasis and explore its clinical applicability. Methods From May 2012 to May 2013,80 patients with liver fibrosis due to Asiatic schistosomiasis treated in our station were selected and evenly divided into experimental group and control group in random.In control group,patients were treated by conventional basic treatment,while in experimental group,Fuzheng Huayu capsule was added.The liver function indexes including ALT,AST,TBiL,Alb,and Glb, liver fibrosis indexes like HA,PC-Ⅲ,Ⅳ-C and LN, transforming growth factor （FGF-β1） in liver tissue before and after treatment, and adverse reaction after medication in two groups were observed. Results There was no statistical difference of liver function indexes,liver fibrosis indexes,or TGF-β1 level after comparison between two groups before treatment （P〉0.05）.After therapy,these above-mentioned indexes were greatly improved and the improvement in experimental group was superior to that in control group （P〈0.05）. Conclusion The effect of Fuzheng Huayu capsule treating liver fibrosis due to Asiatic schistosomiasis is remarkable,and can obviously improve liver function,and it is safe and reliable,which is applicable for long-term clinical application.

关 键 词：扶正化瘀胶囊 日本血吸虫病 肝纤维化 

分 类 号：R532.21[医药卫生—内科学]